Romastru brings Amryt’s cholesterol treatment Lojuxta to Romania and Bulgaria

Amryt has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (Romastru), a Bucharest-based pharmaceutical services company, part of Pharaon Healthcare Europe.

Pharaon Healthcare Europe is a conglomerate which provides a wide range of services, including medical, marketing research, storage and distribution. Amryt holds an exclusive licence to sell Lojuxta for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. 

This is the fourth distribution agreement signed by Amryt in the last three months, and it broadens further the Company’s distribution footprint for Lojuxta in Central and Eastern Europe. The Company aims to complete further agreements across its in-licenced territories in Europe, Middle East and Africa as the year progresses.

Lojuxta is a treatment for Homozygous Familial Hypercholesterolemia (“HoFH”), the rare, life-threatening, genetic cholesterol disorder, and Amryt estimates that there are approximately 30 patients with HoFH in Romania and Bulgaria combined. 

Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said: “Romastru’s reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories.“